불면증 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)
Insomnia Market (Treatment Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonist, Melatonin Antagonist, Devices, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031
상품코드:1420994
리서치사:Transparency Market Research
발행일:2023년 12월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
한글목차
불면증 시장 - 리포트의 범위
세계의 불면증 시장에 관한 TMR의 리포트는 과거와 현재의 성장 동향 및 2023-2031년의 예측 기간 중 시장 지표의 귀중한 인사이트를 얻을 기회를 연구하고 있습니다. 이 리포트는 기간중의 세계 불면증 시장 매출을 제공하고, 2017-2031년의 기간, 2023년을 기준년, 2031년을 예측년으로 간주합니다. 리포트는 2023-2031년 세계의 불면증 시장의 연간 복합 성장률(CAGR %)도 제공합니다.
이 리포트는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 시행되고, 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 제조업체와 인터뷰를 시행했습니다. 2차 조사에는 불면증 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차보고서, 프레스 릴리스 및 관련 문서의 참조가 포함됩니다.
시장 스냅숏
2023년 시장 가치
38억 달러
2031년 시장 가치
64억 달러
CAGR
6%
이 리포트는 세계의 불면증 시장의 경쟁 구도를 상세히 파악하고 있습니다. 세계의 불면증 시장에서 활동하는 주요 기업이 식별되고, 각각의 기업이 다양한 속성의 관점으로부터 프로파일링되고 있습니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 리포트에서 소개되고 있는 세계의 불면증 시장 기업의 속성입니다.
목차
제1장 주요 요약
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
시장 세분화
개요
시장 역학
세계 시장의 분석과 예측, 2017-2031년
제5장 주요 인사이트
파이프라인 분석
주요 국가의 세계 질병 유병률과 이환율
COVID-19 팬데믹이 업계에 미치는 영향
제6장 시장 분석과 예측 : 치료 유형별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 치료 유형별, 2017-2031
벤조디아제핀계
비벤조디아제핀계 약제
항우울제
오렉신 안타고니스트
멜라토닌 안타고니스트
디바이스
기타
시장의 매력 : 치료 유형별
제7장 세계 시장의 분석과 예측 : 판매채널별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 판매채널별, 2017-2031
병원 약국
소매 약국·드러그스토어
온라인 약국
시장의 매력 : 판매채널별
제8장 세계 시장의 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별, 2017-2031
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제9장 북미 시장 분석과 예측
제10장 유럽 시장 분석과 예측
제11장 아시아태평양 시장 분석과 예측
제12장 라틴아메리카 시장 분석과 예측
제13장 중동 및 아프리카 시장 분석과 예측
제14장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업의 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
Paratek Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Teva Pharmaceutical Industries Limited
Vanda Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Sanofi SA
Merck &Co., Inc.
Viatris Inc.
KSA
영문 목차
영문목차
Insomnia Market - Scope of Report
TMR's report on the global insomnia market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global insomnia market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insomnia market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the insomnia market.
Market Snapshot
Market Value in 2023
US$ 3.8 Bn
Market Value in 2031
US$ 6.4 Bn
CAGR
6%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global insomnia market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global insomnia market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global insomnia market.
The report delves into the competitive landscape of the global insomnia market. Key players operating in the global insomnia market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global insomnia market profiled in this report.
Key Questions Answered in Global insomnia Market Report:
What is the sales/revenue generated by insomnia across all regions during the forecast period?
What are the opportunities in the global insomnia market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Insomnia Market - Research Objectives and Research Approach
The comprehensive report on the global insomnia market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global insomnia market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global insomnia market.
Table of Contents
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Insomnia Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Insomnia Market Analysis and Forecasts, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Insomnia Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017-2031
6.3.1. Benzodiazepines
6.3.2. Nonbenzodiazepines
6.3.3. Antidepressants
6.3.4. Orexin Antagonist
6.3.5. Melatonin Antagonist
6.3.6. Devices
6.3.7. Others
6.4. Market Attractiveness, by Treatment Type
7. Global Insomnia Market Analysis and Forecast, by Sales Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Sales Channel, 2017-2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies and Drug Stores
7.3.3. Online Pharmacies
7.4. Market Attractiveness, by Sales Channel
8. Global Insomnia Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Insomnia Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2017-2031
9.2.1. Benzodiazepines
9.2.2. Nonbenzodiazepines
9.2.3. Antidepressants
9.2.4. Orexin Antagonist
9.2.5. Melatonin Antagonist
9.2.6. Devices
9.2.7. Others
9.3. Market Value Forecast, by Sales Channel, 2017-2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies and Drug Stores
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Sales Channel
9.5.3. By Country
10. Europe Insomnia Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017-2031
10.2.1. Benzodiazepines
10.2.2. Nonbenzodiazepines
10.2.3. Antidepressants
10.2.4. Orexin Antagonist
10.2.5. Melatonin Antagonist
10.2.6. Devices
10.2.7. Others
10.3. Market Value Forecast, by Sales Channel, 2017-2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies and Drug Stores
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Sales Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Insomnia Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017-2031
11.2.1. Benzodiazepines
11.2.2. Nonbenzodiazepines
11.2.3. Antidepressants
11.2.4. Orexin Antagonist
11.2.5. Melatonin Antagonist
11.2.6. Devices
11.2.7. Others
11.3. Market Value Forecast, by Sales Channel, 2017-2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies and Drug Stores
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Sales Channel
11.5.3. By Country/Sub-region
12. Latin America Insomnia Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017-2031
12.2.1. Benzodiazepines
12.2.2. Nonbenzodiazepines
12.2.3. Antidepressants
12.2.4. Orexin Antagonist
12.2.5. Melatonin Antagonist
12.2.6. Devices
12.2.7. Others
12.3. Market Value Forecast, by Sales Channel, 2017-2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies and Drug Stores
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Sales Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Insomnia Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017-2031
13.2.1. Benzodiazepines
13.2.2. Nonbenzodiazepines
13.2.3. Antidepressants
13.2.4. Orexin Antagonist
13.2.5. Melatonin Antagonist
13.2.6. Devices
13.2.7. Others
13.3. Market Value Forecast, by Sales Channel, 2017-2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies and Drug Stores
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By Sales Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Paratek Pharmaceuticals, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Treatment Type Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Sumitomo Dainippon Pharma Co., Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Treatment Type Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Teva Pharmaceutical Industries Limited
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Treatment Type Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Vanda Pharmaceuticals Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Treatment Type Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Takeda Pharmaceutical Company Limited
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Treatment Type Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Pfizer Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Treatment Type Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Sanofi S.A
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Treatment Type Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Treatment Type Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Viatris Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
